---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-261221"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2023-10-24T23:59:59+00:00"
generated_at: "2026-06-09T14:15:35.406763+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Aeglea BioTherapeutics posts corporate presentation showing anti-TL1A antibody SPY002 with picomolar potency

## Summary
- Non-clinical data for SPY002 (anti-TL1A antibody) show monomer and trimer binding at picomolar potencies.
- Corporate presentation posted on October 24, 2023, includes updates on research pipeline.
- No new financial results, guidance, or material operational changes disclosed.

## SEC filing metadata
- accession: 0001193125-23-261221
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2023-10-24T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312523261221/0001193125-23-261221-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312523261221/d496165d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-261221
- JSON: https://secwatch.observer/filing/0001193125-23-261221.json
- Plain text: https://secwatch.observer/filing/0001193125-23-261221.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.